PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12P 21/06, 21/04, C07K 1/00, A61K 35/14

A1

(11) International Publication Number: WO 00/34505

(43) International Publication Date: 15 June 2000 (15.06.00)

(21) International Application Number: PCT/US99/29169

(22) International Filing Date: 8 December 1999 (08.12.99)

(30) Priority Data:
09/209,916 10 December 1998 (10.12.98) US

(71) Applicant: BAYER CORPORATION [US/US]; 800 Dwight Way, P.O. Box 1986, Berkeley, CA 94701 (US).

(72) Inventors: CHO, Myung-Sam; 3259 Ramona Street, Pinole, CA 94564 (US). CHAN, Sham, Yuen; 5192 Heavenly Ridge, El Sobrante, CA 94803 (US). KELSEY, William; 101 Bay Park Terrace, Alameda, CA 94112 (US). YEE, Helena; 154 Vienna Street, San Francisco, CA 94112 (US).

(74) Agents: BECK, Michael, J. et al.; Bayer Corporation, 800 Dwight Way, P.O. Box 1986, Berkeley, CA 94701 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.



162162



G00002

(54) Title: EXPRESSION SYSTEM FOR FACTOR VIII

(57) Abstract

This invention describes a protein-free production process for proteins having factor VIII procoagulant activity. Generally, the process includes the derivation of stable human cell clones with high productivity for B-domain deleted Factor VIII, and (2) the adaptation of cells to grow in a medium free of plasma-derived proteins. More specifically, the process includes transfecting human cells with a vector, such as in the figure, comprising a selectable marker and a sequence coding for the protein having factor VIII procoagulant activity, selecting cells with a selection agent, and isolating clones expressing high levels of the protein having factor VIII procoagulant activity.

